SAKAR

Management Guidance & Outlook - Revenue growth guided at 35%+ for FY27 and coming years, with quarterly revenues expected to hit ₹100+ Cr from Q3 FY27. - Oncology segment projected to generate ₹190–₹200 Cr in FY27 and scale to ~₹300 Cr in FY28. - EBITDA margins guided at ~30% near-term, expanding to 34%–35%+ over the next 2 years driven by API backward integration. - Oncology contribution targeted to exceed 60% of overall company revenue over the next 2–3 years. Growth Drivers & Business Pipeline - Executed 69 oncology contracts with discussions ongoing for 45 additional international opportunities. - Submitted 191 dossiers globally with 22 marketing authorizations received across Europe, UK, Canada, and LATAM. - Accord partnership site transfers expected to scale to an average potential of ~₹100 Cr. - 33 technology transfer projects active across 4 CDMO partners, with 21 in-house oncology APIs developed. Capacity & Operational Updates - Plant capacity utilization stands at ~26% for the Bavla facility and 36%–37% for the Changodar facility. - No impact anticipated from domestic trade margin caps on anti-cancer drugs due to B2B/principal export focus.

- Sakar Healthcare provided the audio recording link for its Q2 & H1 FY27 earnings conference call held on October 27, 2026. - Audio recording is made available on the company's official website. - The transcript of the call will be submitted to the exchanges in due course.

- Consolidated Q2 FY27 Revenue grew 52% YoY to ₹87.42 Cr. - EBITDA surged 114% YoY to ₹24.35 Cr; PAT jumped 149% YoY to ₹11.31 Cr. - Executed 69 oncology product contracts with 45 commercial discussions underway. - Received 11 EU/UK site variation approvals; commercial supplies commenced from API-integrated oncology site.

- Sakar Healthcare Limited issued a press release on October 26, 2026. - Relates to Consolidated and Standalone Unaudited Financial Results for Q2 and H1 ended September 30, 2026.

Q2 FY27 Consolidated Revenue ₹87.42Cr vs ₹57.56Cr (▲52% YoY) EBITDA ₹24.35Cr vs ₹11.35Cr (▲114% YoY) PAT ₹11.31Cr vs ₹4.54Cr (▲149% YoY) EBITDA Margin 27.85% vs 19.72% (▲813bps)

Concall Schedule Concall Date: 27th October 2026 Concall Time: 3:00 PM IST

- Sakar Healthcare Limited expands its global export model with oncology products across EU, UK, APAC, Canada, and LatAm regions. - Received 22 Marketing Authorisations out of 190 submitted dossiers and secured 11 site variations for stringent markets. - Two out of seven applied CEPs for in-house developed APIs have been approved, aiding vertical integration. - Commercial supplies have commenced from the EU GMP approved oncology FDF manufacturing site. - Proposed capping on MRP for oncology products in the domestic market will not impact the company as its business is majorly export-skewed.

- Trading window to remain closed from October 1, 2026. - Closure will continue until 48 hours after the declaration of Unaudited Financial Results for the quarter ended September 30, 2026.

- Shareholders/Members of Sakar Healthcare Limited approved the appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for a term of five consecutive years. They will conduct the Secretarial Audit for financial years FY 2026-27 to FY 2030-31. The approval was granted in the 22nd Annual General Meeting held on 22nd September, 2026.

- Sakar Healthcare Ltd. will hold a group meeting with analysts/investors on September 17th & 18th, 2026. - The meeting will be in-person, involving a plant visit and management interaction. - No unpublished price-sensitive information will be shared.

- Investor Meeting Schedule - Meeting Date: September 17th & 18th, 2026 - Meeting Type: In-person Plant Visit and Management interaction with analysts and investors

- Sakar Healthcare Ltd. received 14 new oncology product approvals in the EU, UK & Canada with 7 business partners. - 6 of Sakar's licensed out products were granted Marketing Authorizations (4 in EU, 1 in UK, 1 in Canada). - These approvals enhance market coverage for various cancer types and are expected to drive top-line sales.